Erasca touts strong early results in pancreatic and lung cancer therapy trial
statnews.com • • business
Key Points:
- Erasca reported that its RAS-targeting pill, ERAS-0015, shrank tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer patients, surpassing the company's expectations.
- The preliminary data were gathered from studies conducted in the U.S. and China, showing promising clinical benefits and tolerability.
- ERAS-0015's performance compares favorably to daraxonrasib, a similar drug from Revolution Medicines that recently demonstrated a doubling of overall survival in advanced pancreatic cancer patients.
- Erasca CEO Jonathan Lim highlighted that while lung cancer results are more definitive, the pancreatic cancer data are still maturing but very promising, with all treatment options remaining under consideration.
